Reviewer: James M. Metz, MD
Abramson Cancer Center of the University of Pennsylvania
Last Modified: May 22, 2007
Presenter: Jiamin Li
Presenter's Affiliation: Wanjie Proton Therapy Center, Zibo, China
Type of Session: Scientific
Hepatocellur Carcinoma (HCC) is one of the most common cancers in China and the 4th leading cause of cancer death world wide. Most patients present with advanced stage and 80% are not eligible for surgery at the time of presentation. Conventional radiation therapy is difficult to adminster due to the sensitivity of the normal liver to radiation which reduces the ability to deliver doses high enough to kill the HCC. Radiation induced liver damage (RILD) and destruction of large amounts of normal liver are common with conventional radiation, which has limited its utilzation. Protons can significantly spare normal tissue radiation exposure and may be a viable treatment for these patients with HCC.
Materials and Methods
As the authors state, HCC is a huge problem world wide and many patients are not candidates for surgical resection. Proton therapy may offer an important option for these patients with localized disease. The data presented in this study are consistent with those presented from other centers, particularly in Japan, where proton therapy is offering encouraging results and is becoming a standard treatment option offerered at these centers. Future studies need to better establish the fractionation schedule and total dose most effective for treatment. Efforts should be made towards the earlier stage patients that are not resectable, but still have reasonable liver function.
Sep 29, 2010 - Targeting c-Met, a receptor for hepatocyte growth factor that plays a role in growth, invasion, and metastasis of liver cancer, may be useful in treating patients with hepatocellular carcinoma (HCC) and c-Met positive tumors, according to research presented at the American Association for Cancer Research International Conference on Molecular Diagnostics in Cancer Therapeutic Development, held from Sept. 27 to 30 in Denver.
Sep 29, 2010
Aug 24, 2011